Daniel M. Sullivan

12.3k total citations · 2 hit papers
235 papers, 9.4k citations indexed

About

Daniel M. Sullivan is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Daniel M. Sullivan has authored 235 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Molecular Biology, 89 papers in Oncology and 65 papers in Hematology. Recurrent topics in Daniel M. Sullivan's work include Multiple Myeloma Research and Treatments (54 papers), Cancer therapeutics and mechanisms (43 papers) and Protein Degradation and Inhibitors (32 papers). Daniel M. Sullivan is often cited by papers focused on Multiple Myeloma Research and Treatments (54 papers), Cancer therapeutics and mechanisms (43 papers) and Protein Degradation and Inhibitors (32 papers). Daniel M. Sullivan collaborates with scholars based in United States, Canada and United Kingdom. Daniel M. Sullivan's co-authors include Joel G. Turner, Pamela N. Münster, Adil Daud, Jana L. Dawson, Douglas C. Marchion, Elona Biçaku, Warren E. Ross, Susan Minton, William S. Dalton and Michael D. Latham and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Daniel M. Sullivan

228 papers receiving 9.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

2006 544 citations Daniel M. Sullivan et al. profile →
Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

2008 503 citations Adil Daud, Ronald C. DeConti et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Daniel M. Sullivan

Since Specialization

Citations

This map shows the geographic impact of Daniel M. Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M. Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M. Sullivan more than expected).

Fields of papers citing papers by Daniel M. Sullivan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel M. Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M. Sullivan. The network helps show where Daniel M. Sullivan may publish in the future.

Co-authorship network of co-authors of Daniel M. Sullivan

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel M. Sullivan. A scholar is included among the top collaborators of Daniel M. Sullivan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel M. Sullivan. Daniel M. Sullivan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Recurring Trans-Atlantic Incursion of Clade 2.3.4.4b H5N1 Viruses by Long Distance Migratory Birds from Northern Europe to Canada in 2022/2023 2023 ·Viruses ·Tamiru N. Alkie, Alexander M. P. Byrne, Megan Jones, Benjamin C. Mollett, Laura Bourque, Oliver Lung, Joe James, Carmencita Yason, Ashley C. Banyard, Daniel M. Sullivan, Anthony V. Signore, Andrew S. Lang, Meghan A. Baker, (unknown), Ian H. Brown, Yohannes Berhane	16
2	Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma 2020 ·Cancer Research ·Joel G. Turner, Yan Cui, (unknown), Jana L. Dawson, (unknown), Jongphil Kim, Christopher Cubitt, Taiga Nishihori, William S. Dalton, Daniel M. Sullivan	15
3	Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia 2019 ·Clinical Cancer Research ·Kendra Sweet, Rami S. Komrokji, Eric Padron, Christopher Cubitt, Joel G. Turner, Junmin Zhou, Alan F. List, David A. Sallman, Jana L. Dawson, Daniel M. Sullivan, Julio C. Chávez, Bijal Shah, Jeffrey E. Lancet	22
4	Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM) 2017 ·Blood ·Rachid Baz, Jeffrey A. Zonder, Kenneth H. Shain, Melissa Alsina, Jason Brayer, (unknown), Joel G. Turner, Jana L. Dawson, Jongphil Kim, Daniel M. Sullivan	7
5	Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer 2015 ·Molecular Cancer Therapeutics ·(unknown), Mokenge P. Malafa, Domenico Coppola, Kazim Husain, Sherma Zibadi, Trinayan Kashyap, Marsha Crochiere, Yosef Landesman, Tami Rashal, Daniel M. Sullivan, Amit Mahipal	50
6	Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee 2015 ·Clinical Cancer Research ·Lesley Seymour, Susan Groshen, Gary L. Rosner, Daniel M. Sullivan, David R. Spriggs, Steven A. Reeves, Amy Gravell, S. Percy Ivy, Mark J. Ratain	2
7	Canonical Wnt Pathway Inhibitor ICG-001 Induces Cytotoxicity of Multiple Myeloma Cells in Wnt-Independent Manner 2015 ·PLoS ONE ·(unknown), (unknown), Alexandra Pisklakova, Hao Liu, Daniel M. Sullivan, Yulia Nefedova	38
8	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors 2014 ·Journal of Hematology & Oncology ·L. Rhoda Molife, Yan Li, Joanna Vitfell-Rasmussen, (unknown), Daniel M. Sullivan, Philippe A. Cassier, Eric X. Chen, Andrea Biondo, Ernestina Tetteh, Lillian L. Siu, Amita Patnaik, Kyriakos P. Papadopoulos, Johann S. de Bono, Anthony W. Tolcher, Susan Minton	148
9	Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy 2012 ·Cancer Research ·Rupal Ramakrishnan, Chun Huang, Hyun-Il Cho, Mark C. Lloyd, Joseph Johnson, Xiubao Ren, Soner Altiok, Daniel M. Sullivan, Jeffrey S. Weber, Esteban Celis, Dmitry I. Gabrilovich	90
10	Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates 2011 ·Clinical Cancer Research ·Janelle Perkins, Steven C. Goldstein, Jana L. Dawson, Jongphil Kim, Teresa Field, (unknown), Karen K. Fields, (unknown), (unknown), Anthony Neuger, Richard M. Lush, Daniel M. Sullivan	3
11	Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial 2009 ·Clinical Cancer Research ·Adil Daud, Jana L. Dawson, Ronald C. DeConti, Elona Biçaku, Douglas C. Marchion, (unknown), (unknown), Richard M. Lush, Anthony Neuger, Daniel M. Sullivan, Pamela N. Münster	78
12	Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma breakdown → 2008 ·Journal of Clinical Oncology ·Adil Daud, Ronald C. DeConti, Stephanie Andrews, P. Urbas, Adam I. Riker, Vernon K. Sondak, Pamela N. Münster, Daniel M. Sullivan, Kenneth E. Ugen, Jane L. Messina, Richard Heller	503
13	Signal Transduction Proteins in Tumors From Puerto Rican and Caucasian Gastric Adenocarcinoma Patients: Expression Differences With Potential for Specific Targeted Therapies 2008 ·Digestive Diseases and Sciences ·José L. Cangiano, Barbara A. Centeno, Christopher R. Garrett, (unknown), (unknown), Ji‐Hyun Lee, (unknown), Richard Jove, Luis Báez, Daniel M. Sullivan, Carlos Muro‐Cacho, Teresita Muñoz-Antonia	5
14	Novel 5′ Untranslated Region Variants of BCRP mRNA Are Differentially Expressed in Drug-Selected Cancer Cells and in Normal Human Tissues: Implications for Drug Resistance, Tissue-Specific Expression, and Alternative Promoter Usage 2006 ·Cancer Research ·Takeo Nakanishi, (unknown), Bret A. Hassel, Ken Shiozawa, Daniel M. Sullivan, Joel G. Turner, Douglas D. Ross	53
15	Valproic acid sensitizes human melanoma cells to karenitecin in vitro and in vivo 2006 ·Cancer Research ·Jana Gump, Douglas C. Marchion, Elona Biçaku, Joel G. Turner, Frederick H. Hausheer, Adil Daud, Pamela N. Münster, Daniel M. Sullivan	0
16	T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis 2006 ·Journal of Autoimmunity ·Jorge Allina, Bin Hu, Daniel M. Sullivan, Maria Isabel Fiel, Swan N. Thung, Steven F. Bronk, Robert C. Huebert, Judy Van de Water, Nicholas F. LaRusso, M. Eric Gershwin, Gregory J. Gores, Joseph A. Odin	74
17	Nuclear and cytoplasmic topoisomerase II alpha are differentially phosphorylated and nuclear export is blocked by CRM1 antisense oligonucleotides 2005 ·Cancer Research ·Joel G. Turner, Jana Gump, Bernadette Ferraro, Daniel M. Sullivan	1
18	The absolute bioavailability of oral vinorelbine in patients with solid tumors 2005 ·Cancer Chemotherapy and Pharmacology ·Richard M. Lush, Jeannine S. McCune, Leticia Tetteh, John A. Thompson, J. J. Mahany, Linda L. Garland, A. Benjamin Suttle, Daniel M. Sullivan	24
19	Tumor p53 status and response to topoisomerase II inhibitors 2003 ·Drug Resistance Updates ·Nikola Valkov, Daniel M. Sullivan	28
20	Phosphorylation of the .alpha.- and .beta.-Isoforms of DNA Topoisomerase II Is Qualitatively Different in Interphase and Mitosis in Chinese Hamster Ovary Cells 1994 ·Biochemistry ·D. Andrew Burden, Daniel M. Sullivan	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact